These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 20089648)

  • 1. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.
    Braxton CL; Puckett SH; Mizel SB; Lyles DS
    J Virol; 2010 Apr; 84(7):3552-61. PubMed ID: 20089648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
    Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
    Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
    Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
    J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
    Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors.
    Fang X; Zhang S; Sun X; Li J; Sun T
    Vaccine; 2012 Feb; 30(7):1313-21. PubMed ID: 22222871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.
    Publicover J; Ramsburg E; Rose JK
    J Virol; 2004 Sep; 78(17):9317-24. PubMed ID: 15308726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.
    Rose NF; Roberts A; Buonocore L; Rose JK
    J Virol; 2000 Dec; 74(23):10903-10. PubMed ID: 11069984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.
    Kapadia SU; Simon ID; Rose JK
    Virology; 2008 Jun; 376(1):165-72. PubMed ID: 18396306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.
    Majid AM; Ezelle H; Shah S; Barber GN
    J Virol; 2006 Jul; 80(14):6993-7008. PubMed ID: 16809305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol.
    Ramsburg E; Rose NF; Marx PA; Mefford M; Nixon DF; Moretto WJ; Montefiori D; Earl P; Moss B; Rose JK
    J Virol; 2004 Apr; 78(8):3930-40. PubMed ID: 15047809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdovirus-based vaccine platforms against henipaviruses.
    Kurup D; Wirblich C; Feldmann H; Marzi A; Schnell MJ
    J Virol; 2015 Jan; 89(1):144-54. PubMed ID: 25320306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
    Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
    J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
    Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
    Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
    Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
    J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus.
    Ahmed M; Marino TR; Puckett S; Kock ND; Lyles DS
    J Virol; 2008 Sep; 82(18):9273-7. PubMed ID: 18614644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
    Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.
    Haglund K; Leiner I; Kerksiek K; Buonocore L; Pamer E; Rose JK
    J Virol; 2002 Aug; 76(15):7506-17. PubMed ID: 12097563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.
    Nasar F; Matassov D; Seymour RL; Latham T; Gorchakov RV; Nowak RM; Leal G; Hamm S; Eldridge JH; Tesh RB; Clarke DK; Weaver SC
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.
    Kahn JS; Roberts A; Weibel C; Buonocore L; Rose JK
    J Virol; 2001 Nov; 75(22):11079-87. PubMed ID: 11602747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.